Cutaneous responses to allergen after local pretreatment with beta-adrenoceptor stimulating and blocking agents.
beta-Adrenoceptor stimulating agents possess anti-allergic effects in vitro and in vivo. To study the mechanism of action further we compared in 10 atopic subjects the effects on allergen-induced cutaneous reactions of intradermally (i.d.) injected prenalterol (1-10 microgram) terbutaline (2.5-250 ng) and KWD 2131 (100 ng-2.5 microgram), i.e. compounds with preferential actions on beta 1-, beta 2-adrenoceptors and on beta-adrenoceptors not fitting this classification. All injections were given according to a double-blind design. Terbutaline and KWD 2131 produced a dose-dependent inhibition of the skin reactions induced by injecting horse dander allergen 5 min later. Terbutaline was about 20 times as potent as KWD 2131 whereas prenalterol was inactive. Propranolol fully blocked the anti-allergic effect produced by terbutaline. The results suggest that the cutaneous anti-allergic effect of beta-adrenoceptor-stimulating drugs is mediated via activation of beta 2-adrenoceptors, possibly on the mast cell, resulting in inhibition of mediator release.
D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000328:Adult; D000485:Allergens / Q000276:immunology; D000937:Antigen-Antibody Reactions / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000276:immunology*; D007428:Intradermal Tests; D011217:Practolol / Q000031:analogs & derivatives / Q000494:pharmacology; D011294:Prenalterol; D011433:Propranolol / Q000494:pharmacology; D012867:Skin / Q000276:immunology; D013726:Terbutaline / Q000031:analogs & derivatives / Q000494:pharmacology
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D000485:Allergens; C025075:KWD 2131; D011433:Propranolol; D011294:Prenalterol; D013726:Terbutaline; D011217:Practolol